From: Smith, Michael (CBER)
Sent: Wednesday, August 4, 2021 4:48 PM
To: Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>; Rohlfing, Paul <Paul.Rohlfing@pfizer.com>
Cc: Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>
Subject: STN 125742.0: Comments on LRP template submitted to STN 125742/0.14 on 7/20

Elisa,

The review team has the below comments on the lot release protocol (LRP) template that was submitted to BLA 125742/0.14 on July 20, 2021. The review team has requested that responses are submitted to the BLA by Wednesday, August 11, 2021. We anticipate responding to Paul's clarification questions on the LRP and samples that were e-mailed us yesterday in the near future.

Throughout document

Please correct the cc: line to STN 125742-0/2229/FC

Page 1 of 6

Please replace with the attached example (Attachment 1 – Electronic Protocol Page 1)

Please make sure that the electronic Protocol Number at the bottom of Page 1 matches the number on the eLRP Signature letter.

Information after the Date of Manufacturing line and before the Storage Temperature is optional.

Note: When submitting LRPs electronically, please use a letter formatted per Attachment 2 – eLRP Signature letter. Place this letter before the electronic protocol.

Page 2 of 6

Components table

- Please add component description for the LNP

Page 3 of 6

- RNA Encapsulation and RNA content.
  Please use the RNA content template (Attachment 3) to report the results

- Lipid analysis
  Please provide full (b) (4) of the lipid components for the sample, (b) (4) (b) (4) Insert the (b) (4) for the reference standard above the sample lines and label all the (b) (4) The page on which the (b) (4) are provided should include a table with test date, specifications and results for each lipid content and identity.

Page 4 of 6

- Table 1 (Continued) Filled Vaccine Quality Control Tests
  Please remove the abbreviations for (b) (4) (b) (4) (b) (4). These tests are not performed for the filled vaccine.

- Identity of encoded RNA sequence
  Please use the identity test template (Attachment 4) to report the drug product test results

- In vitro expression
  Please use the in vitro expression test template (Attachment 5) to report the drug product test results

- RNA integrity
  Please provide (b) (4) that are (b) (4) RNA (b) (4) for each sample replicate and insert the reference standard (b) (4) above this line so that the sample lines are not obscured. Please include clear labels for product and (b) (4) (b) (4) that were included in the analysis of each (b) (4). Include the name of the test method, the specification, date of test and the result on the same page as the (b) (4).
- Bacterial endotoxin

Please use the Limulus Amebocyte Lysate Test template (Attachment 6) to report the drug product endotoxin results.

- Sterility
  Method: Please add (b) (4) Method to (b) (4)

  Container: Please change 20 mL to (b) (4)

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

Mike Smith, Ph.D.
Captain, USPHS

Senior Regulatory Review Officer
Food and Drug Administration
Center for Biologics Evaluation & Research
Office of Vaccines Research & Review
Division of Vaccines and Related Products Applications
Tel: 301-796-2640
michael.smith2@fda.hhs.gov